A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation
Ernie Anand,1 Lovisa Berggren,2 Claudia Deix,3 Ágoston Tóth,4 David P McDonnell5 1Neuroscience Medical Affairs – EU, Eli Lilly, Windlesham, United Kingdom; 2Global Statistical Sciences, Lilly Deutschland GmbH, Bad Homburg, Germany; 3Neuroscience, Eli Lilly Regional O...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2015
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/8d5b267f3f554425b7cf329f8a710e0c |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:8d5b267f3f554425b7cf329f8a710e0c |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:8d5b267f3f554425b7cf329f8a710e0c2021-12-02T07:21:29ZA 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation1178-2021https://doaj.org/article/8d5b267f3f554425b7cf329f8a710e0c2015-05-01T00:00:00Zhttp://www.dovepress.com/a-6-year-open-label-study-of-the-efficacy-and-safety-of-olanzapine-lon-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Ernie Anand,1 Lovisa Berggren,2 Claudia Deix,3 Ágoston Tóth,4 David P McDonnell5 1Neuroscience Medical Affairs – EU, Eli Lilly, Windlesham, United Kingdom; 2Global Statistical Sciences, Lilly Deutschland GmbH, Bad Homburg, Germany; 3Neuroscience, Eli Lilly Regional Operations GmbH, Vienna, Austria; 4Lilly Hungary, Budapest, Hungary; 5Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA Purpose: To assess the long-term efficacy and safety of olanzapine long-acting injection (LAI) in the treatment of schizophrenia, focusing on clinical trial data consistent with the approved indication and dosing recommendations in the European label and which forms the basis for treatment decisions made by clinicians in daily clinical practice.Patients and methods: This was a post hoc analysis of a 6-year open-label study of olanzapine LAI in patients (male or female, 18–75 years old) with schizophrenia entering this study following feeder studies of olanzapine LAI. Patients were flexibly dosed (45–405 mg, 2- to 4-week intervals), but those receiving oral olanzapine supplementation whose total olanzapine dose was >20 mg/day equivalent were excluded from this post hoc analysis.Results: Data from 669 patients were analyzed (44.5% completed). Positive and Negative Syndrome Scale total scores did not change significantly from baseline to endpoint; Clinical Global Impression-Severity scores improved significantly. Mean weight change was +2.19 kg (P<0.001), with 40.8% of patients experiencing ≥7% weight gain. There were 24 occurrences of post-injection delirium/sedation syndrome (PDSS).Conclusion: Olanzapine LAI appeared to be effective in the long-term maintenance of schizophrenia, and the safety profile was consistent with that of oral olanzapine, except for injection-related events and PDSS events. Keywords: antipsychotic, depot, long-acting injection, olanzapine, pamoate, schizophreniaAnEBerggren LDeix CTóth ÁMcDonnell DPDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2015, Iss default, Pp 1349-1357 (2015) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 |
| spellingShingle |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 An E Berggren L Deix C Tóth Á McDonnell DP A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation |
| description |
Ernie Anand,1 Lovisa Berggren,2 Claudia Deix,3 Ágoston Tóth,4 David P McDonnell5 1Neuroscience Medical Affairs – EU, Eli Lilly, Windlesham, United Kingdom; 2Global Statistical Sciences, Lilly Deutschland GmbH, Bad Homburg, Germany; 3Neuroscience, Eli Lilly Regional Operations GmbH, Vienna, Austria; 4Lilly Hungary, Budapest, Hungary; 5Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA Purpose: To assess the long-term efficacy and safety of olanzapine long-acting injection (LAI) in the treatment of schizophrenia, focusing on clinical trial data consistent with the approved indication and dosing recommendations in the European label and which forms the basis for treatment decisions made by clinicians in daily clinical practice.Patients and methods: This was a post hoc analysis of a 6-year open-label study of olanzapine LAI in patients (male or female, 18–75 years old) with schizophrenia entering this study following feeder studies of olanzapine LAI. Patients were flexibly dosed (45–405 mg, 2- to 4-week intervals), but those receiving oral olanzapine supplementation whose total olanzapine dose was >20 mg/day equivalent were excluded from this post hoc analysis.Results: Data from 669 patients were analyzed (44.5% completed). Positive and Negative Syndrome Scale total scores did not change significantly from baseline to endpoint; Clinical Global Impression-Severity scores improved significantly. Mean weight change was +2.19 kg (P<0.001), with 40.8% of patients experiencing ≥7% weight gain. There were 24 occurrences of post-injection delirium/sedation syndrome (PDSS).Conclusion: Olanzapine LAI appeared to be effective in the long-term maintenance of schizophrenia, and the safety profile was consistent with that of oral olanzapine, except for injection-related events and PDSS events. Keywords: antipsychotic, depot, long-acting injection, olanzapine, pamoate, schizophrenia |
| format |
article |
| author |
An E Berggren L Deix C Tóth Á McDonnell DP |
| author_facet |
An E Berggren L Deix C Tóth Á McDonnell DP |
| author_sort |
An |
| title |
A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation |
| title_short |
A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation |
| title_full |
A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation |
| title_fullStr |
A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation |
| title_full_unstemmed |
A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation |
| title_sort |
6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the european label recommendation |
| publisher |
Dove Medical Press |
| publishDate |
2015 |
| url |
https://doaj.org/article/8d5b267f3f554425b7cf329f8a710e0c |
| work_keys_str_mv |
AT an a6yearopenlabelstudyoftheefficacyandsafetyofolanzapinelongactinginjectioninpatientswithschizophreniaaposthocanalysisbasedontheeuropeanlabelrecommendation AT e a6yearopenlabelstudyoftheefficacyandsafetyofolanzapinelongactinginjectioninpatientswithschizophreniaaposthocanalysisbasedontheeuropeanlabelrecommendation AT berggrenl a6yearopenlabelstudyoftheefficacyandsafetyofolanzapinelongactinginjectioninpatientswithschizophreniaaposthocanalysisbasedontheeuropeanlabelrecommendation AT deixc a6yearopenlabelstudyoftheefficacyandsafetyofolanzapinelongactinginjectioninpatientswithschizophreniaaposthocanalysisbasedontheeuropeanlabelrecommendation AT totha a6yearopenlabelstudyoftheefficacyandsafetyofolanzapinelongactinginjectioninpatientswithschizophreniaaposthocanalysisbasedontheeuropeanlabelrecommendation AT mcdonnelldp a6yearopenlabelstudyoftheefficacyandsafetyofolanzapinelongactinginjectioninpatientswithschizophreniaaposthocanalysisbasedontheeuropeanlabelrecommendation AT an 6yearopenlabelstudyoftheefficacyandsafetyofolanzapinelongactinginjectioninpatientswithschizophreniaaposthocanalysisbasedontheeuropeanlabelrecommendation AT e 6yearopenlabelstudyoftheefficacyandsafetyofolanzapinelongactinginjectioninpatientswithschizophreniaaposthocanalysisbasedontheeuropeanlabelrecommendation AT berggrenl 6yearopenlabelstudyoftheefficacyandsafetyofolanzapinelongactinginjectioninpatientswithschizophreniaaposthocanalysisbasedontheeuropeanlabelrecommendation AT deixc 6yearopenlabelstudyoftheefficacyandsafetyofolanzapinelongactinginjectioninpatientswithschizophreniaaposthocanalysisbasedontheeuropeanlabelrecommendation AT totha 6yearopenlabelstudyoftheefficacyandsafetyofolanzapinelongactinginjectioninpatientswithschizophreniaaposthocanalysisbasedontheeuropeanlabelrecommendation AT mcdonnelldp 6yearopenlabelstudyoftheefficacyandsafetyofolanzapinelongactinginjectioninpatientswithschizophreniaaposthocanalysisbasedontheeuropeanlabelrecommendation |
| _version_ |
1718399465919873024 |